Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.68 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11689691 | 0.98 | SIGMAR1 (0.66) | SIGMAR1TMEM97CYP3A4HSD17B10OPRL1 | |
| SCHEMBL24358373 | 0.94 | SIGMAR1 (0.61) | SIGMAR1TMEM97CYP3A4HSD17B10OPRL1 | |
| SCHEMBL10120597 | 0.90 | SIGMAR1 (0.56) | SIGMAR1TMEM97CYP3A4HSD17B10OPRL1 | |
| SCHEMBL3837603 | 0.88 | SIGMAR1 (0.56) | SIGMAR1TMEM97CYP3A4HSD17B10OPRL1 | |
| SCHEMBL6186488 | 0.85 | OPRM1 (0.52) | SIGMAR1TMEM97CYP3A4HSD17B10OPRL1 | |
| SCHEMBL13131259 | 0.84 | CYP2D6 (0.53) | SIGMAR1TMEM97CYP3A4ALDH1A1TSHR | |
| SCHEMBL17879559 | 0.84 | SIGMAR1 (0.50) | SIGMAR1TMEM97CYP3A4HSD17B10OPRL1 | |
| SCHEMBL3780476 | 0.83 | HRH3 (0.56) | SIGMAR1TMEM97HRH3ALDH1A1MEN1 | |
| SCHEMBL8739456 | 0.83 | HRH3 (0.56) | SIGMAR1TMEM97HRH3ALDH1A1TSHR | |
| SCHEMBL16084375 | 0.83 | SIGMAR1 (0.53) | SIGMAR1TMEM97CYP3A4HSD17B10OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4076443-B1 | SUBSTITUTED 1,3,8-TRIAZASPIRO[4,5]DECANE-2,4-DIONE COMPOUND AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20220396577-A1 | NOVEL SUBSTITUTED 1,3-8-TRIAZASPIRO[4,5] DECANE-2,4-DIONE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-12-15 | — | — | US | disclosed |
| EP-4076443-A1 | NOVEL SUBSTITUTED 1,3,8-TRIAZASPIRO[4,5]DECANE-2,4-DIONE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TDO) INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021126725-A1 | NOVEL SUBSTITUTED 1,3,8-TRIAZASPIRO[4,5]DECANE-2,4-DIONE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-10138253-B2 | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2018-11-27 | — | — | US | disclosed |
| EP-3334741-A1 | IMIDAZOPYRIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-06-20 | — | — | EP | disclosed |
| US-20180044323-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | SUZHOU ZELGEN BIOPHARMACEUTICALS CO LTD (CN) | 2018-02-15 | — | — | US | disclosed |
| US-9834566-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834566-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834566-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-12-05 | — | — | US | disclosed |
| WO-2017025913-A1 | IMIDAZOPYRIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-02-16 | — | — | WO | disclosed |
| WO-2015126743-A1 | PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-27 | — | — | WO | disclosed |
| WO-2015126743-A1 | PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-27 | — | — | WO | disclosed |
| US-8951938-B2 | Combinatorial rosamine library to detect cell-state switching | NEW YORK UNIVERSITY (US) | 2015-02-10 | — | — | US | disclosed |
| US-8951938-B2 | Combinatorial rosamine library to detect cell-state switching | NEW YORK UNIVERSITY (US) | 2015-02-10 | — | — | US | disclosed |
| US-8026110-B2 | For detecting and imaging cells; solid phase synthesis | NEW YORK UNIVERSITY (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090227467-A1 | COMBINATORIAL ROSAMINE LIBRARY TO DETECT CELL-STATE SWITCHING | NEW YORK UNIVERSITY (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227467-A1 | COMBINATORIAL ROSAMINE LIBRARY TO DETECT CELL-STATE SWITCHING | NEW YORK UNIVERSITY (US) | 2009-09-10 | — | — | US | disclosed |
| US-20080124751-A1 | COMBINATORIAL ROSAMINE LIBRARY AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2008-05-29 | — | — | US | disclosed |
| US-4018922-A | NEUROLEPTICS, ANALGESICS, SPASMOLYTICS, AND ANTIHISTAMINES | ROUSSEL-UCLAF (FR) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124751-A1 | COMBINATORIAL ROSAMINE LIBRARY AND USES THEREOF | RXFP1, RXFP2, CX3CR1 | SIGMAR1 867/4885TMEM97 448/4885CYP3A4 2267/4885 |
| US-20180044323-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | DCK, DPYD, BRAF | SIGMAR1 4788/4885TMEM97 4477/4885CYP3A4 3062/4885 |
| US-20220396577-A1 | NOVEL SUBSTITUTED 1,3-8-TRIAZASPIRO[4,5] DECANE-2,4-DIONE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TDO) INHIBITORS | IDO1, IDO2, TDO2 | SIGMAR1 2921/4885TMEM97 4081/4885CYP3A4 1005/4885 |
| US-10138253-B2 | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication | TYMP, TYMS, CCNI | SIGMAR1 3513/4885TMEM97 3849/4885CYP3A4 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.